Mixed Bipolar I Disorder — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for mixed bipolar i disorder. 405 active patents protecting 5 drugs from 5+ originators. First major cliff: 2026. Daily refresh.

5
Approved drugs
405
Active US patents
54/100
Avg vulnerability
$3.3B
Annual revenue covered

Originators in Mixed Bipolar I Disorder

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Otsuka/BMS) 214 patents Johnson & Johnson (Janssen) 110 patents Eli Lilly 56 patents Hisamitsu 18 patents Novartis AG (originally Geigy) 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating mixed bipolar i disorder. Each bar = one year. Y-axis scaled to peak year (76 patents).

28
26
35
27
20
28
57
29
48
30
76
31
30
32
63
33
8
34
18
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Abilify
aripiprazole
 Generic (originally Otsuka/BMS) 214 61 $3.0B 2026-07-28
Risperdal
risperidone
 Johnson & Johnson (Janssen) 110 56 — 2026-06-26
Zyprexa
olanzapine
 Eli Lilly 56 64 $300M 2031-08-23
Saphris
ASENAPINE
 Hisamitsu 18 33 — 2033-07-25
Tegretol
carbamazepine
 Novartis AG (originally Geigy) 7 55 — 2028-11-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
12194035 Zyprexa method of use 81 2031-08-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9687474 Saphris formulation 25 2033-07-25
10022445 Saphris formulation 25 2033-07-25
10022445 Saphris formulation 25 2033-07-25
11123305 Saphris formulation 25 2033-07-25
9687474 Saphris formulation 25 2033-07-25
9687474 Saphris formulation 25 2033-07-25

Related